Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Int J Gynecol Cancer ; 24(9 Suppl 3): S61-6, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25341583

ABSTRACT

OBJECTIVES: The Gynecologic Cancer InterGroup aimed to provide an overview of uterine and ovarian leiomyosarcoma management. METHODS: Published articles and author experience were used to draft management overview. The draft manuscript was circulated to international members of the Gynecologic Cancer InterGroup for review and comment, and appropriate revisions were made. RESULTS: The approach to management of uterine and ovarian leiomyosarcoma management is reviewed. CONCLUSIONS: Uterine and ovarian leiomyosarcomas are rare and aggressive cancers that require specialized expertise for optimal management.


Subject(s)
Leiomyosarcoma/pathology , Medical Oncology , Ovarian Neoplasms/pathology , Practice Guidelines as Topic , Uterine Neoplasms/pathology , Combined Modality Therapy , Consensus , Female , Humans , Leiomyosarcoma/therapy , Ovarian Neoplasms/therapy , Societies, Medical , Uterine Neoplasms/therapy
2.
Obstet Gynecol ; 124(2 Pt 1): 307-315, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25004343

ABSTRACT

OBJECTIVE: To estimate lower extremity lymphedema prevalence in patients surgically treated for endometrial cancer, identify predictors of lymphedema, and evaluate the effects of lymphedema on quality of life. METHODS: One thousand forty-eight consecutive patients who were operated on between 1999 and 2008 at the Mayo Clinic were mailed a survey, which included our validated 13-item lymphedema screening questionnaire and two validated quality-of-life measures. Logistic regression models were fit to identify factors associated with prevalent lymphedema; a multivariable model was obtained using stepwise and backward variable selection methods. The relationship between lymphedema and obesity with each quality-of-life score was evaluated separate multivariable linear models. RESULTS: There were 591 responders (56%) after exclusions. Our questionnaire revealed a previous self-reported lymphedema diagnosis in 103 (17%) patients and identified undiagnosed lymphedema in 175 (30%) (overall prevalence 47.0%, median 6.2 years follow-up). Lymphedema prevalence in patients treated with hysterectomy alone compared with lymphadenectomy was 36.1% and 52.3%, respectively (attributable risk 23%). Lymphedema risk was not associated with the number of nodes removed or the extent of lymphadenectomy after adjusting for other factors. On multivariable analysis, higher body mass index, congestive heart failure, performance of lymphadenectomy, and radiation therapy were associated with prevalent lymphedema. Multiple quality-of-life scores were worse in women with lymphedema. CONCLUSION: The attributable risk of developing lower extremity lymphedema was 23% for patients with endometrial cancer who underwent lymphadenectomy compared with hysterectomy alone with an overall prevalence of 47%. Lymphedema was associated with reductions in multiple quality-of-life domains. LEVEL OF EVIDENCE: II.


Subject(s)
Endometrial Neoplasms/surgery , Hysterectomy/adverse effects , Lymph Node Excision/adverse effects , Lymphedema/epidemiology , Aged , Body Mass Index , Endometrial Neoplasms/radiotherapy , Female , Follow-Up Studies , Heart Failure/complications , Humans , Lower Extremity , Lymphedema/diagnosis , Lymphedema/etiology , Middle Aged , Prevalence , Quality of Life , Risk Factors , Surveys and Questionnaires
3.
Am J Obstet Gynecol ; 207(5): 379.e1-6, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22964067

ABSTRACT

OBJECTIVE: We sought to estimate cytologically benign endometrial cell (CBEC)-associated endometrial hyperplasia and cancer rates, and describe clinical and histologic outcomes. STUDY DESIGN: Medical records of women age >40 years with CBEC in 2005 through 2010 were reviewed for clinical characteristics; assessment with endometrial biopsy, ultrasound, or hysteroscopy; and consequent outcomes. RESULTS: Of 658 women, 281 (42.7%) were assessed: 39.4% of 330 premenopausal, and 46.0% of 328 postmenopausal women. Among these, cancer rate was 3.6% and differed between premenopausal (0.8%) and postmenopausal (6.0%) women (P = .019). Hyperplasia rate was similar in premenopausal (3.9%) and postmenopausal (3.3%) women. Of 20 assessed women with endometrial pathology, 4 (1 premenopausal) women with cancer and 4 (2 premenopausal) women with hyperplasia had no abnormal bleeding. CONCLUSION: Cancer was more common in postmenopausal women with assessed CBEC while hyperplasia was comparably distributed between premenopausal and postmenopausal women. Findings support CBEC assessment regardless of menopausal status or abnormal bleeding.


Subject(s)
Endometrial Hyperplasia/epidemiology , Endometrial Hyperplasia/pathology , Endometrial Neoplasms/epidemiology , Endometrial Neoplasms/pathology , Endometrium/pathology , Adult , Biopsy , Endometrium/diagnostic imaging , Female , Humans , Hysteroscopy , Incidence , Middle Aged , Polyps/diagnostic imaging , Polyps/epidemiology , Polyps/pathology , Postmenopause , Premenopause , Treatment Outcome , Ultrasonography
4.
Cancer Res ; 70(3): 875-82, 2010 Feb 01.
Article in English | MEDLINE | ID: mdl-20103634

ABSTRACT

Edmonston vaccine strains of measles virus (MV) have shown significant antitumor activity in preclinical models of ovarian cancer. We engineered MV to express the marker peptide carcinoembryonic antigen (MV-CEA virus) to also permit real-time monitoring of viral gene expression in tumors in the clinical setting. Patients with Taxol and platinum-refractory recurrent ovarian cancer and normal CEA levels were eligible for this phase I trial. Twenty-one patients were treated with MV-CEA i.p. every 4 weeks for up to 6 cycles at seven different dose levels (10(3)-10(9) TCID(50)). We observed no dose-limiting toxicity, treatment-induced immunosuppression, development of anti-CEA antibodies, increase in anti-MV antibody titers, or virus shedding in urine or saliva. Dose-dependent CEA elevation in peritoneal fluid and serum was observed. Immunohistochemical analysis of patient tumor specimens revealed overexpression of measles receptor CD46 in 13 of 15 patients. Best objective response was dose-dependent disease stabilization in 14 of 21 patients with a median duration of 92.5 days (range, 54-277 days). Five patients had significant decreases in CA-125 levels. Median survival of patients on study was 12.15 months (range, 1.3-38.4 months), comparing favorably to an expected median survival of 6 months in this patient population. Our findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients.


Subject(s)
Carcinoembryonic Antigen/metabolism , Measles virus/physiology , Oncolytic Viruses/physiology , Ovarian Neoplasms/therapy , Abdominal Pain/etiology , Adult , Aged , Aged, 80 and over , Animals , Carcinoembryonic Antigen/genetics , Chlorocebus aethiops , Fatigue/etiology , Female , Fever/etiology , Humans , Injections, Intraperitoneal , Measles virus/genetics , Middle Aged , Neoplasm Recurrence, Local , Oncolytic Virotherapy/adverse effects , Oncolytic Virotherapy/methods , Oncolytic Viruses/genetics , Ovarian Neoplasms/pathology , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/adverse effects , Treatment Outcome , Vero Cells
5.
Ann Thorac Surg ; 81(6): 2004-7, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16731120

ABSTRACT

BACKGROUND: Little information is available regarding long-term survival after pulmonary metastasectomy for gynecologic malignancies. METHODS: All patients who underwent pulmonary resection for gynecologic malignancies at our institution between January 1985 and June 2001 were reviewed. Factors affecting long-term survival were analyzed. RESULTS: There were 103 patients, 70 of whom had metastatic disease limited to the lungs. Median age of these 70 patients was 59.4 years (range, 31 to 80 years). The primary tumor originated in the uterine corpus in 37 patients, endometrium in 23, cervix in 7, ovaries in 2, and vagina in 1. Histopathology was leiomyosarcoma in 29 patients, adenocarcinoma in 23, other sarcoma in 11, squamous cell carcinoma in 5, and choriocarcinoma and endolymphatic stromal myosis in 1 each. The median time interval between the first gynecologic procedure and pulmonary resection was 24 months (range, 0 to 237 months). A wedge excision was performed in 44 patients, lobectomy in 14, bilobectomy in 2, pneumonectomy in 1, and a combination in 9. Five patients (7%) had an incomplete resection. Eighteen patients (25.7%) developed at least one complication and 1 died (operative mortality, 1.4%). At last follow-up, 35 had died, and the median follow-up among those who were still alive was 36 months (range, 6 months to 13 years). Five-year and 10-year survival was 46.8% (95% confidence interval, 34.2% to 63.0%) and 34.3% (95% confidence interval, 19.7% to 52.5%), respectively. Factors that adversely affected survival include a disease-free interval between the first gynecologic procedure and pulmonary resection of less than 24 months (p = 0.004) and a primary site located in the cervix (p < 0.001). CONCLUSIONS: Pulmonary resection for metastatic gynecologic cancer in selected patients is safe and effective. Both a short disease-free interval between the primary gynecologic procedure and pulmonary metastasectomy, and a primary cervical tumor had an adverse effect on survival.


Subject(s)
Genital Neoplasms, Female/mortality , Lung Neoplasms/secondary , Pneumonectomy/statistics & numerical data , Adenocarcinoma/mortality , Adenocarcinoma/secondary , Adenocarcinoma/surgery , Adenocarcinoma/therapy , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/secondary , Carcinoma, Squamous Cell/surgery , Carcinoma, Squamous Cell/therapy , Chemotherapy, Adjuvant , Choriocarcinoma/mortality , Choriocarcinoma/secondary , Choriocarcinoma/surgery , Choriocarcinoma/therapy , Combined Modality Therapy , Disease-Free Survival , Endometrial Stromal Tumors/mortality , Endometrial Stromal Tumors/secondary , Endometrial Stromal Tumors/surgery , Endometrial Stromal Tumors/therapy , Female , Follow-Up Studies , Genital Neoplasms, Female/therapy , Humans , Hysterectomy , Leiomyosarcoma/mortality , Leiomyosarcoma/secondary , Leiomyosarcoma/surgery , Leiomyosarcoma/therapy , Life Tables , Lung Neoplasms/mortality , Lung Neoplasms/surgery , Lymph Node Excision , Middle Aged , Ovarian Neoplasms/mortality , Ovarian Neoplasms/therapy , Ovariectomy , Pneumonectomy/methods , Postoperative Complications/mortality , Radiotherapy, Adjuvant , Retrospective Studies , Risk Factors , Sarcoma/mortality , Sarcoma/secondary , Sarcoma/surgery , Sarcoma/therapy , Survival Analysis , Uterine Cervical Neoplasms/mortality
6.
Mayo Clin Proc ; 79(10): 1277-82, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15473410

ABSTRACT

OBJECTIVE: To investigate presenting signs and symptoms of ovarian cancer and stage of tumor in a community cohort of women with the diagnosis of ovarian cancer. PATIENTS AND METHODS: We reviewed retrospectively the medical records of all women who sought primary and specialty care in Olmsted County, Minnesota, between January 1, 1985, and December 31, 1997, to evaluate presenting symptoms, time from first symptom to diagnosis of ovarian cancer, and stage of tumor at diagnosis. RESULTS: Of 107 women with a diagnosis of ovarian cancer, the most commonly documented presenting symptom was crampy abdominal pain. Urinary symptoms and abdominal pain were the most commonly documented presenting symptom in patients with stage I and II ovarian cancers, whereas abdominal pain and increased abdominal girth were the most commonly documented symptoms in patients with stage III and IV cancer. Approximately 15% of tumors (n = 15) were found during routine evaluations or during a procedure for another problem. Less than 25% of presenting symptoms (n = 24 women) related directly to the pelvis or were more traditional gynecologic symptoms. Delays in women seeking medical care, health care system issues, competing medical conditions, physicians' failure to follow up, and women not returning for follow-up were associated with longer time to diagnosis. CONCLUSION: Both stage I and II cancer are associated with symptoms, but few symptoms are directly related to the reproductive pelvic organs or unique to ovarian cancer. A longer interval from first sign or symptom to diagnosis of ovarian cancer is associated with both patient and health care system factors.


Subject(s)
Neoplasms, Glandular and Epithelial/diagnosis , Ovarian Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Humans , Middle Aged , Minnesota/epidemiology , Neoplasm Staging , Neoplasms, Glandular and Epithelial/epidemiology , Neoplasms, Glandular and Epithelial/pathology , Ovarian Neoplasms/epidemiology , Ovarian Neoplasms/pathology , Patient Acceptance of Health Care , Retrospective Studies , Time Factors , Urban Population
SELECTION OF CITATIONS
SEARCH DETAIL
...